US 12,458,639 B2
Tubulin binding compounds and therapeutic use thereof
Lan Huang, New York, NY (US); Santosh Ambadas Khedkar, Lexington, MA (US); and Michel O. Steinmetz, Villigen (CH)
Assigned to BeyondSpring Pharmaceuticals, Inc., New York, NY (US)
Filed by BeyondSpring Pharmaceuticals, Inc., New York, NY (US)
Filed on Apr. 24, 2023, as Appl. No. 18/306,191.
Application 18/306,191 is a division of application No. 16/476,242, granted, now 11,633,393, previously published as PCT/US2018/012668, filed on Jan. 5, 2018.
Claims priority of provisional application 62/443,247, filed on Jan. 6, 2017.
Prior Publication US 2024/0082243 A1, Mar. 14, 2024
Int. Cl. C07D 403/06 (2006.01); A61K 31/495 (2006.01); A61K 31/496 (2006.01); A61P 35/00 (2006.01); C07D 411/06 (2006.01)
CPC A61K 31/496 (2013.01) [A61K 31/495 (2013.01)] 2 Claims
 
1. A method of treating or inhibiting the progression of cancer selected from the group consisting of breast cancer, colon cancer, rectal cancer, lung cancer, prostate cancer, melanoma, leukemia, ovarian cancer, gastric cancer, renal cell carcinoma, liver cancer, pancreatic cancer, lymphomas and myeloma, the method comprising:
administering to a subject in need thereof a compound selected from the group consisting of:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.